Comparing the effectiveness of panitumumab combined with FOLFOX4 treatment in patients with colon cancer vs. rectal cancer

Abstract

The greatest cause of cancer-related fatalities globally is colorectal cancer (CRC). Targeted therapies like panitumumab are revolutionizing its treatment. Our study focuses on the impact of KRAS and NRAS genotypes on the efficacy of panitumumab and also on the significance of tumor location (colon vs. rectum) in treatment outcomes. We selected a specific clinical trial (NCT00364013) for further statistical analysis. Our work adds to what has already been learned by showing that KRAS and NRAS genotypes are important for how well panitumumab works to treat CRC. Meanwhile, the P-value of 0.49 demonstrated that, in contrast to what we had previously believed, the tumor site had no significant impact on progression-free survival outcomes. Our research highlights the critical role of genotyping in personalized CRC therapy and raises questions about the established opinion that tumor location impacts therapy outcomes significantly. These findings may help CRC management move toward a more genotype-centric approach, optimizing therapies and reducing expenses. Nevertheless, future studies with more significant cohorts would be needed to confirm these findings, given the larger sample size.